As an industry, we regularly discuss the benefits of adopting risk-based quality management (RBQM). The good news is that adoption is on the increase with companies implementing RBQM in 57% of clinical trials.
However, there is still a way to go before RBQM becomes business as usual, and adoption rates are lower among smaller companies.
So, what are the potential negative impacts of failing to implement RBQM?
Steve Young, Chief Scientific Officer at CluePoints, discusses the risks companies who fail to adopt RBQM may be leaving themselves susceptible to.
International Clinical Trials, August 2024, pages 75-77. © Samedan Ltd
